Birmingham, MI December 2, 2013 -- The Cutaneous Lymphoma Foundation (CLF) Board of Directors is pleased to welcome Christopher Shipp as its new President. Mr. Shipp has served on the Board since 2005 and held positions as both Vice President and Treasurer.
“I am delighted to announce the Board of Directors has chosen Christopher Shipp to serve as our new President. Chris has extensive knowledge in the healthcare field having held various leadership positions over the last 15 years and has been a long-term, committed member of the CLF Board. In addition to his professional expertise in strategic marketing, Chris is a cutaneous lymphoma survivor and personally understands the importance of the work of the CLF,” said Susan Thornton, CEO, Cutaneous Lymphoma Foundation. “It is exciting to have Chris step into the leadership role as Board President, and we all look forward to working with him in this new capacity.”
The Foundation is also happy to announce the addition of three new board members.
Steven M. Horwitz, MD, Memorial-Sloan Kettering Cancer Center, focuses on the care of patients with all types of lymphomas. More specifically, his research focuses on developing a better understanding of new therapies for patients with less-common types of lymphoma, including T-cell lymphomas and cutaneous lymphomas.
Dr. Horwitz has led numerous clinical trials, and his research has appeared in a number of medical publications, including the American Journal of Hematology, Clinical Advances of Hematology and Oncology, Clinical Lymphoma, Myeloma, and Leukemia, Journal of Clinical Oncology, Journal of the American Academy of Dermatology, and the Journal of the National Comprehensive Cancer Network, among others.
Dr. Horwitz has been a longtime friend of the CLF and has distinguished himself as a global leader in both physician and patient education on the topic of cutaneous T-cell lymphoma. He has participated in numerous CLF patient education forums and has written for the CLF Forum newsletter. He has also generously donated his time to participate in numerous webcasts, podcasts and workshops providing education, advocacy and support to the CTCL community. He has also served on the board of the U.S. Cutaneous Lymphoma Consortium (USCLC) and served on various committees for the International Society for Cutaneous Lymphomas.
Lauren Pinter-Brown, MD, UCLA Jonsson Comprehensive Cancer Center, has been on the UCLA staff since 1990 and the Director of their Lymphoma Program since 2005. She has an extensive background and focus in T-cell lymphomas and concentrates on optimizing treatment for patients diagnosed with lymphomas. She is the principal investigator for clinical research protocols for patients with Hodgkin's disease, B-cell lymphomas, CD30+ Anaplastic large-cell lymphoma and T-cell lymphomas.
Dr. Pinter-Brown has been a member of the CLF’s Medical Advisory Board since 2000, and has provided editorial and speaking services. She has been an editorial contributor to the CLF’s Forum and has served as a reviewer for many medical publications, including The American Journal of Hematology, Journal of Clinical Dermatology and Journal of Clinical Oncology. She also lectures extensively on leukemia, T-cell lymphoma and cutaneous T-cell lymphoma.
Dr. Pinter-Brown also serves on the Board of Directors of the United States Cutaneous Lymphoma Consortium and is a member of the American Society of Clinical Oncology, American Society of Hematology and the International Society for Cutaneous Lymphoma, among others. She has held various positions with patient advocacy organizations, including the Lymphoma Research Foundation and Ted Mann Family Resource Center.
Mike Silver is a Vice President at a leading Canadian Investment Bank, where he is responsible for structuring and executing on mergers, acquisitions and financing transactions. He has worked in the investment banking industry since 2006, having held other positions in the banking industry, both in Canada and the U.S. Prior to earning his MBA, Mike worked with IBM for three years within several finance and strategy-related positions. Mike is also a cutaneous lymphoma survivor.
“We are privileged to have such gifted and well-informed individuals who can help the organization continue its mission to provide high-quality services to all patients living with cutaneous lymphoma and their families,” said Thornton. “It is an honor to welcome each of these passionate individuals to the Board of Directors”.
About Cutaneous Lymphomas
Cutaneous lymphomas are cancers of lymphocytes (white blood cells) that primarily involve the skin. Classification is based on lymphocyte type: B-lymphocytes (B-cell) or T-lymphocytes (T-cell). Cutaneous T-cell lymphoma (CTCL) is the most common type of cutaneous lymphoma that typically presents with red, scaly patches or thickened plaques of skin that often mimic eczema or chronic dermatitis. Progression from limited skin involvement is variable and may be accompanied by tumor formation, ulceration and exfoliation and complicated by itching and infections. Advanced stages are defined by involvement of lymph nodes, peripheral blood and internal organs.
Cutaneous lymphomas affect thousands of individuals worldwide, with approximately 30,000 people having been diagnosed in North America. It is estimated that 3,000 new cases are diagnosed each year in the US.
About the Cutaneous Lymphoma Foundation
The Cutaneous Lymphoma Foundation is an independent, nonprofit patient advocacy organization whose mission is to support every person with cutaneous lymphoma by promoting awareness and education, advancing patient care and facilitating research. The Cutaneous Lymphoma Foundation was founded in 1998, and it is the only organization worldwide that offers comprehensive programs and services that provide information, resources and support to people affected by cutaneous lymphoma. For more information, please visit www.clfoundation.org or contact the Foundation at (248) 644-9014 or .
This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.